Ana
Echarri Piudo
Publicacións (79) Publicacións de Ana Echarri Piudo
2024
-
Contraceptive Recommendations for Women with Immune-Mediated Inflammatory Diseases: A Delphi Consensus
Advances in Therapy, Vol. 41, Núm. 4, pp. 1372-1384
-
Implementation of a Teledermatology Electronic Consultation Program to Improve the Care of Patients with Inflammatory Bowel Disease
Telemedicine Reports, Vol. 5, Núm. 1, pp. 12-17
-
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease
Gastroenterologia y Hepatologia
2023
-
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10
-
Optimizing treatment of mild to moderate ulcerative colitis: CU-forum Delphi consensus
Gastroenterologia y Hepatologia, Vol. 46, Núm. 10, pp. 784-794
-
Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives
Telemedicine journal and e-health : the official journal of the American Telemedicine Association, Vol. 29, Núm. 10, pp. 1504-1513
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 128-140
-
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 118-127
-
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study
Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176
-
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 4, pp. 294-306
2021
-
Effectiveness of ustekinumab in fistulising perianal Crohn′s disease refractory or intolerant to anti-TNF
Journal of Crohn's and Colitis, Vol. 15, Núm. Supplement_1, pp. S419-S420
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
-
Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa — GETECCU) on dysplasia screening in inflammatory bowel disease patients
Gastroenterologia y Hepatologia, Vol. 44, Núm. 6, pp. 435-447
-
Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
Journal of Crohn's and Colitis, Vol. 15, Núm. Supplement_1, pp. S018-S020
2020
-
INTRALESIONAL INJECTION OF ADALIMUMAB IN INTESTINAL STRICTURES OF PATIENTS WITH CROHN’S DISEASE: A RANDOMIZED, MULTICENTER, PROSPECTIVE CLINICAL TRIAL
Gastrointestinal Endoscopy, Vol. 91, Núm. 6, pp. AB277
-
The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study
Telemedicine and e-Health, Vol. 26, Núm. 1, pp. 80-88
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854
-
Letter: double‐dose intensification – a quick way to reverse antibody formation and loss of response in patients treated with adalimumab
Alimentary Pharmacology & Therapeutics, Vol. 49, Núm. 6, pp. 821-822